{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:38:13Z","timestamp":1792546693838,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.arteri.2019.10.002","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T18:09:18Z","timestamp":1574878158000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S2","title":["Control del perfil lip\u00eddico global"],"prefix":"10.1016","volume":"31","author":[{"given":"Mariano","family":"Blasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Ascaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2019.10.002_bib0220","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2019.10.002_bib0225","first-page":"301","article-title":"Importancia de la dislipidemia en la enfermedad cardiovascular: un punto de vista","volume":"27","author":"Ascaso","year":"2015","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.arteri.2019.10.002_bib0230","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2019.10.002_bib0235","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2019.10.002_bib0240","doi-asserted-by":"crossref","first-page":"E1189","DOI":"10.1503\/cmaj.101280","article-title":"Efficacy of statins for primary prevention in people at low cardiovascular risk: A meta-analysis","volume":"183","author":"Tonelli","year":"2011","journal-title":"CMAJ"},{"key":"10.1016\/j.arteri.2019.10.002_bib0245","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/0300060513476428","article-title":"A review of statin use in patients with acute coronary syndrome in Western and Japanese populations","volume":"41","author":"Miyauchi","year":"2013","journal-title":"J Int Med Res"},{"key":"10.1016\/j.arteri.2019.10.002_bib0250","doi-asserted-by":"crossref","first-page":"418","DOI":"10.4103\/2230-8210.183460","article-title":"Triglyceride and cardiovascular risk: A critical appraisal","volume":"20","author":"Singh","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.arteri.2019.10.002_bib0255","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s00125-011-2336-9","article-title":"Prevalence of diabetes mellitus and impaired glucose regulation in Spain: The Di@bet.es Study","volume":"55","author":"Soriguer","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.arteri.2019.10.002_bib0260","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0953-6205(03)00022-0","article-title":"Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population","volume":"14","author":"Ascaso","year":"2003","journal-title":"Eur J Intern Med"},{"issue":"Suppl B","key":"10.1016\/j.arteri.2019.10.002_bib0265","first-page":"85B","article-title":"Metabolic syndrome: A marker of patients at high cardiovascular risk","volume":"22","author":"Lau","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.arteri.2019.10.002_bib0270","first-page":"86","article-title":"Documento de consenso sobre el manejo de la dislipidemia aterog\u00e9nica de la Sociedad Espa\u00f1ola de Arteriosclerosis","volume":"29","author":"Ascaso","year":"2017","journal-title":"Clin Invest Arterioscler"},{"key":"10.1016\/j.arteri.2019.10.002_bib0275","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00129784-200707010-00004","article-title":"Management of dyslipidemia in the metabolic syndrome: Recommendations of the Spanish HDL-Forum","volume":"7","author":"Ascaso","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.arteri.2019.10.002_bib0280","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrcardio.2017.31","article-title":"Hypertriglyceridaemia and risk of coronary artery disease","volume":"14","author":"Reiner","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.arteri.2019.10.002_bib0285","first-page":"265","article-title":"La aut\u00e9ntica dimensi\u00f3n del colesterol-no-HDL: colesterol aterog\u00e9nico","volume":"28","author":"Mill\u00e1n","year":"2016","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.arteri.2019.10.002_bib0290","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2019.10.002_bib0295","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.amjcard.2017.01.033","article-title":"Relation of fasting triglyceride-rich lipoprotein cholesterol to coronary artery calcium score (from the ELSA-Brasil Study)","volume":"119","author":"Bittencourt","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arteri.2019.10.002_bib0300","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4065\/mcp.2009.0517","article-title":"Using apolipoprotein B to manage dyslipidemic patients: Time for a change?","volume":"85","author":"Harper","year":"2010","journal-title":"May Clin Proc"},{"key":"10.1016\/j.arteri.2019.10.002_bib0305","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jacl.2011.02.001","article-title":"Clinical implications of discordance between low-density lipoprotein cholesterol and particle number","volume":"5","author":"Otvos","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2019.10.002_bib0310","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.arteri.2019.10.002_bib0315","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1742-1241.2012.02998.x","article-title":"Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population","volume":"67","author":"Martinez-Hervas","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.arteri.2019.10.002_bib0320","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.amjcard.2010.05.002","article-title":"Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control","volume":"106","author":"Carey","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arteri.2019.10.002_bib0325","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1046\/j.1365-2362.1998.00317.x","article-title":"Retention of fluorescent-labelled chylomicron remnantswithin the intima of the arterial wall\u2014evidence that plaque cholesterol may be derived from post-prandial lipoproteins","volume":"28","author":"Proctor","year":"1998","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.arteri.2019.10.002_bib0330","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","article-title":"Atherogenesis: A postprandial phenomenon","volume":"60","author":"Zilversmit","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2019.10.002_bib0335","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1161\/01.CIR.94.8.2013","article-title":"Stability and instability: Two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995","volume":"94","author":"Davies","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2019.10.002_bib0340","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nrcardio.2012.182","article-title":"HDL cholesterol studies-more of the same?","volume":"10","author":"Despr\u00e9s","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.arteri.2019.10.002_bib0345","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2019.10.002_bib0350","first-page":"188","article-title":"Los fibratos en la prevenci\u00f3n primaria de la enfermedad cardiovascular. Resultados de una revisi\u00f3n sistem\u00e1tica de la colaboraci\u00f3n Cochrane","volume":"30","author":"Brea","year":"2018","journal-title":"Clin Invest Arterioscler"},{"key":"10.1016\/j.arteri.2019.10.002_bib0355","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trialwith gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2019.10.002_bib0360","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2019.10.002_bib0365","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2019.10.002_bib0370","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2019.10.002_bib0375","article-title":"Fibrates for secondary prevention of cardiovascular disease and stroke (review)","volume":"25","author":"Wang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.arteri.2019.10.002_bib0380","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: Meta-analysis of randomized controlled trials including 117,411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"Br Med J"},{"key":"10.1016\/j.arteri.2019.10.002_bib0385","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate of rhabdomyolisis with fenofibrate + statin versus gemfibrozil + any statin","volume":"95","author":"Jones","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arteri.2019.10.002_bib0390","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2019.10.002_bib0395","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2019.10.002_bib0400","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjcard.2009.05.020","article-title":"Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force\/Texas Coronary Atherosclerosis Prevention Study)","volume":"104","author":"Cui","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arteri.2019.10.002_bib0405","first-page":"295","article-title":"Terapia con fibratos: uso racional del fenofibrato 2016. Resumen ejecutivo","volume":"28","author":"Brea","year":"2016","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.arteri.2019.10.002_bib0410","doi-asserted-by":"crossref","first-page":"60B","DOI":"10.1016\/S0002-9149(98)00040-X","article-title":"Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia","volume":"81","author":"Ellen","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arteri.2019.10.002_bib0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-13-26","article-title":"Residual macrovascular risk in 2013: what have we learned?","volume":"13","author":"Fruchart","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.arteri.2019.10.002_bib0420","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1185\/03007995.2010.489341","article-title":"International Steering Committee of R(3)i Implications of the ACCORD Lipid study: Perspective from the Residual Risk Reduction Initiative (R3i)","volume":"26","author":"Fruchart","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.arteri.2019.10.002_bib0425","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1161\/CIRCULATIONAHA.108.768986","article-title":"Medication adherence: Its importance in cardiovascular outcomes","volume":"119","author":"Ho","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2019.10.002_bib0430","first-page":"20","article-title":"Consecuci\u00f3n de objetivos terap\u00e9uticos","volume":"26 Supl 1","author":"Mantilla","year":"2014","journal-title":"Clin Invest Arterioscl"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916819301214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916819301214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:31:56Z","timestamp":1759325516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916819301214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":43,"alternative-id":["S0214916819301214"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2019.10.002","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Control del perfil lip\u00eddico global","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2019.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}